Plasma Asymmetric Dimethylarginine and Decompensation of HF
Plasma Asymmetric Dimethylarginine and Decompensation of HF
In conclusion, an elevated circulating level of ADMA is a strong independent predictor of short-term and long-term mortality in patients with decompensation of CHF and reduced left ventricular ejection fraction. ADMA levels upon presentation may confer enhanced risk stratification in this setting. Further studies are warranted to confirm the incremental value of ADMA over current risk-stratifying tools in patients with decompensation of CHF.
Conclusion
In conclusion, an elevated circulating level of ADMA is a strong independent predictor of short-term and long-term mortality in patients with decompensation of CHF and reduced left ventricular ejection fraction. ADMA levels upon presentation may confer enhanced risk stratification in this setting. Further studies are warranted to confirm the incremental value of ADMA over current risk-stratifying tools in patients with decompensation of CHF.
